Bioline Rx Ltd ADR Dossier
Qualitative Analysis
Business overview
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a clinical-stage biopharmaceutical company focused on the development and advancement of therapies in oncology and rare diseases. The company's lead approved product is APHEXDA (motixafortide), indicated in the United States for stem cell mobilization for autologous transplantation in multiple myeloma. Following a strategic shift in late 2024, BioLineRx out-licensed global commercialization rights for APHEXDA (excluding Asia) to Ayrmid Pharma and Asian rights to Gloria Biosciences, shutting down its independent U.S. commercial operations to transition back to a lean, development-focused model in Israel. The company is currently advancing motixafortide in metastatic pancreatic cancer (PDAC) and sickle cell disease (SCD), alongside its newly co-developed asset GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing GLIX1, a first-in-class oral small molecule targeting DNA damage response by restoring TET2 activity, through a Phase 1/2a clinical trial in recurrent and progressive glioblastoma.
Expected impact: Establishes safety, recommended dose, and clinical proof-of-concept for a novel oncology asset targeting hard-to-treat brain cancers.
Supporting the Columbia University-led Phase 2b CheMo4METPANC trial evaluating motixafortide in combination with cemiplimab and standard chemotherapy for metastatic pancreatic ductal adenocarcinoma (mPDAC).
Expected impact: Expands the clinical utility and market potential of motixafortide beyond stem cell mobilization into solid tumor indications.
Leveraging out-licensing agreements with Ayrmid (globally, excluding Asia and solid tumors) and Gloria Biosciences (in Asia) to drive commercial adoption of APHEXDA and expand clinical development in sickle cell disease and regional SCM trials.
Expected impact: Generates non-dilutive royalty and milestone revenue to fund internal R&D while expanding global market reach.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Established Tetragon Biosciences Ltd., a joint venture to develop GLIX1 and other DNA repair-focused molecules. BioLineRx holds an initial 40% economic stake, which can increase up to 70% as it manages and funds development.
Terms: No upfront payment; BioLineRx funds development activities to increase its equity stake. The JV holds first-look rights to other molecules in Hemispherian's pipeline.
Exclusive license to commercialize APHEXDA (motixafortide) globally (excluding Asia) for stem cell mobilization and to develop it in other indications like sickle cell disease.
Terms: BioLineRx receives tiered royalties on sales (ranging from 18% to double digits) and is eligible for up to $287 million in commercial milestones.
Exclusive license to develop and commercialize motixafortide across all indications in Asia.
Terms: Includes development and commercial milestones, plus tiered royalties on net sales in Asian territories.